Targeting endothelial dysfunction in hypertensive subjects

Journal of Human Hypertension

Volumn 19, Issue , 2005, Pages S21-S25

  Thuillez, C ^a   Richard, V ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

Antihypertensive drugs; Converting enzyme inhibitors; Diuretics; Endothelium; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; LACIDIPINE; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PERINDOPRIL; PRETERAX; SUPEROXIDE;

ADRENERGIC SYSTEM; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ARTERY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOCRINE EFFECT; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; DEGRADATION; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTENSION; INFLAMMATION; MEDICAL ASSESSMENT; NONHUMAN; OXIDATIVE STRESS; PARACRINE SIGNALING; PATHOPHYSIOLOGY; RIGIDITY; SHEAR STRESS; TARGET ORGAN; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; VASODILATATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION;

EID: 21744440586     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001889     Document Type: Article

References (33)

1. Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rats. Hypertension 1986; 8: 344–348.
2. Nakamura T, Prewitt RL. Alteration of endothelial function in arterioles of renal hypertensive rats at two levels of vascular tone. J Hypertens 1992; 10: 621–627.
3. Lu¨ scher TF, Raij L, Vanhoutte PM. Endotheliumdependent vascular responses to acetylcholine in normotensive and hypertensive Dahl rats. Hypertension 1987; 9: 157–163.
4. Linder L, Kiowski W, Buhler FR, Lu¨ scher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation 1990; 81: 1762–1767.
5. Taddei S. Vitamin C improves endotheliumdependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation 1998; 97: 2222–2229.
6. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87: 1468–1474.
7. Antony I, Lerebours G, Nitenberg A. Angiotensinconverting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115–3122.
8. Taddei S. Lacidipine restores endotheliumdependent vasodilation in essential hypertensive patients. Hypertension 1997; 30: 1606–1612.
9. Ghiadoni L. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35(1 Part 2): 501–506.
10. De Caterina R. Nitric oxide decreases cytokineinduced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60–66.
11. Artigues C. Increased endothelium-monocyte interactions in salt-sensitive hypertension: effect of L-arginine. J Cardiovasc Pharmacol 2000; 35: 468–473.
12. Capers IV Q. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997; 30: 1397–1402.
13. Perticone F. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191–196.
14. Zhou MS. L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. J Hypertens 2001; 19: 421–429.
15. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032–2037.
16. Boger RH. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.
17. Surdacki S. Reduced urinary excretion of nitric oxide metabolites and increases plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–658.
18. Cosentino F, Lu¨ scher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999; 43: 274–278.
19. Landmesser U. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201–1209.
20. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endotheliumderived relaxing factor. Nature 1986; 320: 454–460.
21. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactive endothelium derived relaxing factor. Am J Physiol 1986; 250: H822–H827.
22. Mehta JL, Lopez LM, Chen L, Cox OE. Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol 1994; 74: 901–990.
23. Sagar S. Oxygen free radicals in essential hypertension. Mol Cell Biochem 1992; 111: 103–108.
24. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990; 16: 532–540.
25. Richard V. Fixed dose combination of perindopril with indapamide in spontaneously hypertensive rats: hemodynamic, biological and structural effects. J Hypertens 1996; 14: 1447–1454.
26. Joannides R. Administration of low-dose combination of an angiotensin-converting enzyme inhibitor and a diuretic improves conduit artery endothelial function in essential hypertension. J Hypertens 2004; 22(Suppl 2): S123.
27. Joannides R. Administration of low-dose combination of perindopril and indapamide improves conduit artery endothelial function in essential hypertension. Eur Heart J 2004; 25: 97.
28. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997; 96: 2407–2413.
29. Taddei S. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16: 447–456.
30. Ghiadoni L. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–1286.
31. Taddei S. Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19: 1379–1386.
32. Cockcroft JR. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO dependent mechanism. J Pharmacol Exp Ther 1995; 374: 1067–1071.
33. Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. Clin Pharmacol Ther 2001; 69: 238–244.